Premier Research中国
  • Capabilities
    • Overview
    • Product Development Consulting
      • Overview
      • Development Consulting
      • Global Regulatory Consulting
      • Nonclinical Studies
      • Chemistry, Manufacturing, and Controls
      • Quality Assurance
      • Commercial
      • Global Compliance
      • Medical Affairs
    • Clinical Research & Development
      • Overview
      • Biometrics
      • Study Design
      • Biostatistics
      • Medical Writing
      • Premier IRT
      • Study Start-Up
      • Quality Management & QA
      • Safety & Pharmacovigilance
      • Project Management
      • Data Management
      • Combination Products
    • Real-World & Late Phase
    • Premier Ecosystem
    • Functional Service Provider
  • Expertise
    • Overview
    • Rare Disease
    • Cell & Gene Therapy
    • Oncology & Hematology
    • Dermatology
    • MedTech
      • Diagnostics
      • Medical Device
      • Digital Therapeutics
    • Neuroscience
    • Pediatrics
    • Analgesia
    • Women’s Health
    • Other Experience
  • Insights
    • Premier Perspectives Blog
    • Resource Center
    • Frequently Asked Questions
  • About Us
    • Our Approach
    • Leadership
    • Corporate Responsibility
    • News
    • Events
    • Locations
    • Investigators
    • Contact Us
  • Careers
Request Information

Premier Perspectives

The blog for insider insights in clinical development

Medical and Regulatory Affairs

ANDA or 505(b)(2): Choosing the Right Abbreviated Approval Pathway for Your Drug

By Rahul Chandrasekhar

June 29, 2021

Premier Research中国
  • Corp. Policy
  • Privacy
  • Cookies
  • Investigators
  • News
  • Careers
© 2025 Premier Research中国
© 2025 Premier Research中国
  • 中文 (简体)